



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/17, 31/541, C07C 275/18, 275/28, C07D 279/12		A1	(11) International Publication Number: WO 00/41685 (43) International Publication Date: 20 July 2000 (20.07.00)
(21) International Application Number: PCT/US00/01252 (22) International Filing Date: 19 January 2000 (19.01.00)		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/116,359 19 January 1999 (19.01.99) US 60/117,187 26 January 1999 (26.01.99) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<p>(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): DHANAK, Dashyant [GB/US]; 1502 West Woodbank Way, West Chester, PA 19380 (US).</p> <p>(74) Agents: SIMON, Soma, G. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).</p>			

(54) Title: CCR-3 RECEPTOR ANTAGONISTS

(57) Abstract

CCR-3 receptor antagonists and novel methods for their use are provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

CCR-3 RECEPTOR ANTAGONISTSFIELD OF THE INVENTION

The present invention relates to the use of phenylalanine amide derivatives, and pharmaceutical compositions containing these compounds as Chemokine/CCR-5 receptor antagonists.

Chemokines are a superfamily of small secreted proteins. There are approximately 30 distinct chemokines known with many others being characterized. See Oppenheim et al., Properties of the Novel Proinflammatory Supergene "Intercrine" Cytokine Family, Ann. Rev. Immun., 9, 617-648 (1991); and 10 Baggioolini, et al., Interleukin-8 and Related Chemotactic Cytokines-CXC and CC Chemokines, Adv. Immun., 55, 97-179 (1994). The properties of the chemokines suggest that they are essential for leukocyte trafficking and inflammatory processes, and are thus important components in a number of disease states. See Kita et al., Chemokines Active on Eosinophils: Potential Roles in Allergic Inflammation, J. 15 Exp. Med., 183, 2421-2426 (1996); Strieter, et al., "The Good, the Bad and the Ugly" The Role of Chemokines in Models of Human Diseases, J. Immun., 157, 3583-3586 (1996); and Baggioolini, Eotaxin: a VIC (Very Important Chemokine) of Allergic Inflammation, J. Clin. Invest., 97, 587 (1996).

Chemokines mediate their effects via interactions with 7TM-G-protein 20 coupled receptors on the surface of immune and inflammatory cells. Eosinophils are proinflammatory granulocytes that play a major role in allergic diseases, such as bronchial asthma, allergic rhinitis, pruritis and atopic dermatitis. Upon activation, eosinophils release lipid mediators, cytotoxic proteins, oxygen metabolites and cytokines, all of which have the potential to produce pathophysiology. Numerous 25 studies have demonstrated the presence of eosinophils or eosinophil-specific products in inflamed tissues in human diseases.

The mechanisms responsible for the selective infiltration of eosinophils in 30 allergic diseases have yet to be clarified. Recently, a CC chemokine, Eotaxin, was identified in guinea pigs and demonstrated to be present in a guinea pig model of allergic airway inflammation. See Jose, et al., Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in Guinea Pig Model of Allergic Airways

Inflammation, J. Exp. Med., 179, 881-887 (1994); and Jose, et al., Eotaxin: Cloning of an Eosinophil Chemoattractant Cytokine and Increased mRNA Expression in Allergen-challenged Guinea-pig Lungs, Biochem. Biophys. Res. Comm., 205, 788-794 (1994). The human homologue of Guinea-pig eotaxin has been expressed and 5 has been shown to induce eosinophil infiltration when injected into the skin of the rhesus monkey. See Ponath, et al., Cloning of the Human Eosinophil Chemoattractant, Eotaxin: Expression, Receptor Binding, and Functional Properties Suggest a Mechanism for Selective Recruitment of Eosinophils, J. Clin. Invest., 97, 604-612 (1996).

10 The cloning, expression and characterization of a novel C-C chemokine receptor, designated CCR-3 from peripheral blood eosinophils and from an eosinophil cDNA library have also been reported. See Kitaura, et al., Molecular Cloning of Human Eotaxin, an Eosinophil-selective CC Chemokine, and Identification of a Specific Eosinophil Eotaxin Receptor, CC Chemokine Receptor 3, 15 J. Biol. Chem., 271, 7725-7730 (1996); Ahuja, et al., Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor, J. Biol. Chem., 270, 16491-16494 (1995); Daugherty, et al., Cloning, Expression and Characterization of the Human Eosinophil Eotaxin Receptor, J. Exp. Med., 183, 2349-2354 (1996); and Ponath, et al., Molecular Cloning and Characterization of a Human Eotaxin Receptor 20 Expressed Selectively on Eosinophils, J. Exp. Med., 183, 2437-2448 (1996).

Eotaxin, MCP-4 and, to a lesser extent, RANTES and MCP-3 activate this receptor. The CCR-3 receptor is expressed at high levels on eosinophils; typically 40,000- 400,000 receptors per cell are present. This is 10-100 fold more than the other chemokine receptor (CCR-1) expressed in eosinophils. Monoclonal antibodies 25 raised to the CCR-3 receptor demonstrate that the receptor is primarily restricted to eosinophils and a subset of Th2 T-cells. This restricted expression on eosinophils and T-cells may be responsible for the selective recruitment of eosinophils and Th2 T-cells in allergic inflammation. Additionally, CCR-3 is potently activated by eotaxin 1, eotaxin and MCP-4. See Stellato et al., Production of the Novel CC 30 Chemokine MCP-4 by Airway Cells and Comparison of Its Biological Activity to other CC-Chemokines, J. Clin. Invest., 99, 926-936 (1997). In contrast, other known

chemokines appear to activate more than one chemokine receptor, e.g. RANTES binds to CCR-1, CCR-3, CCR-4 and CCR-5 receptors.

The foregoing research advances have provided the impetus to investigate the inhibition of eosinophil-specific chemokines in order to examine its role in blocking 5 cellular infiltration in inflamed tissues. CCR-3 receptor antagonists thus offer a unique approach toward decreasing the pathophysiology associated with allergic diseases. Antagonism of this receptor may be useful in the treatment of allergic disorders, including but not limited to bronchial asthma, allergic rhinitis, eczema, nasal polypsis, conjunctivitis, atopic dermatitis, inflammatory bowel disorder and 10 pruritis.

SUMMARY OF THE INVENTION

The present invention involves (S)-2-[2-(1-naphthoylamino)-3-4-nitrophenyl)propionylamino]-(N-phenyl)propionamide or N-(2-bromophenyl)-N'-[4-chloro-2-hydroxy-3-(1-oxidothiomorpholinosulfonyl)phenyl] urea, or 15 pharmaceutically acceptable salts thereof, and their use as CCR-3 receptor antagonists. Such compounds are useful in the treatment of a variety of diseases associated with allergic disorders, including but not limited to bronchial asthma, eczema, allergic rhinitis, conjunctivitis, nasal polypsis, atopic dermatitis, pruritis and inflammatory bowel disease.

20 The present invention further provides methods for antagonizing CCR-3 receptors in an animal, including humans, which comprises administering to a subject in need of treatment an effective amount of a present compound.

DETAILED DESCRIPTION OF THE INVENTION

The present compounds, (S)-2-[2-(1-naphthoylamino)-3-4-nitrophenyl)propionylamino]-(N-phenyl)propionamide and N-(2-bromophenyl)-N'-[4-chloro-2-hydroxy-3-(1-oxidothiomorpholinosulfonyl)phenyl] urea, are useful as 25 CCR-3 receptor antagonists.

The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active 30 forms. All of these compounds and diastereomers are contemplated to be within the scope of the present invention.

In order to use the present compound or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

5 As used herein, "treatment" of a disease includes, but is not limited to prevention, retardation and prophylaxis of the disease.

10 The present compounds are useful for the treatment of diseases including but not limited to bronchial asthma, eczema, allergic rhinitis, conjunctivitis, nasal polyposis, atopic dermatitis, pruritis and inflammatory bowel disease.

The present compounds and pharmaceutically acceptable salts may be administered in a standard manner for the treatment of the indicated diseases, for example orally, parenterally, sub-lingually, dermally, transdermally, rectally, via inhalation or via buccal administration.

15 The present compound and pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules, creams and lozenges. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or
20 coloring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell.
25 Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.

30 Typical parenteral compositions consist of a solution or suspension of a compound or salt in a sterile aqueous or non-aqueous carrier optionally

containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.

Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the 5 form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.

A typical suppository formulation comprises the present compound or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric 10 glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs.

Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or 15 membrane.

Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose.

Each dosage unit for oral administration contains suitably from 0.1 20 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg/Kg, of the compound or a pharmaceutically acceptable salt thereof calculated as the free acid. Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person. A 25 topical formulation contains suitably 0.01 to 5.0% of the present compound.

The daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of the present compound or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, of 30 the compound or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for intranasal administration and oral

inhalation is suitably about 10 to about 500 mg/person. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.

5 No unacceptable toxicological effects are expected when compounds of the present invention are administered in accordance with the present invention.

The biological activity of the present compounds is demonstrated by the following test:

Human eosinophils were purified by standard CD16 cell depletion using a
10 Miltenyi cell separation column and a magnetic Super Macs magnet. Eosinophils which were >95% pure as assessed by DiffQuick staining and light microscopy were washed in PBS and resuspended in binding buffer (RPMI-1640 + 25mM Hepes + 0.1% Gelatin + 0.1% sodium azide + 0.008% CHAPS). Into a 96 well plate (Dynatek) 200,000 eosinophils, 0.25 nM 125I-Eotaxin (Amersham Plc), and
15 compound of interest (1 nM to 100 uM) was added. This mixture of cells compound and ligand was allowed to incubate for 60 min at room temperature before harvesting. For harvesting, free ligand from bound ligand was separated over a Packard Unifilter-96 GFC, (cat #6005174) which had been pre-blocked with 1% polyethylenimine (Sigma Cat # P3143) and 1% Bovine Serum Albumin (BSA) for 2
20 hours prior to use. After drying, and sealing the plate with Topseal (Packard Topseal A Cat # 6005185) 50 ul of MicroScint (Packard Microscint-20 Cat # 6013621) was added to each well. Bound from free 125I-eotaxin was separated using a Packard Filtermate 196, 96-well plate harvester. To determine total and non-specific binding (NSB) three wells for each condition were set aside. For total binding and NSB, 25 wells received all additions except compound. In addition NSB wells received 200 nM cold eotaxin (PeproTech, Rocky Hill, NJ). Radioactivity associated with the filter was assessed in a Packard Top-count Microplate Scintillation Counter model number 49872V. Percent control binding was assessed by first subtracting the NSB from each well and then expressing the number of counts (CPM) associated with the 30 compound treated sample as a percent of the control binding in the absence of compound addition.

Animal model for the *in vivo* evaluation of CCR-3 antagonistsGuinea pig bronchoalveolar lavage (BAL) model(Gonzalo, J.A. et al, Immunity, 1996, 4, 1.)

5 BALs were obtained from Guinea Pigs (\pm compound) 24 h after ovalbumin (OA) exposure to eotaxin administered via inhalation. The animals were euthanized by cervical dislocation and exsanguinated. The lungs were lavaged with 50 ml of DulBecco's PBS (5x10cc), which was aspirated after a gentle chest massage. The BAL fluid was spun down and the pellet was resuspended in 0.25% NaCl to lyse 10 residual erythrocytes. After centrifugation, the pellet was resuspended again in 0.9% NaCl. After a total cell count, slides were prepared and stained. The cells were differentiated into eosinophils, neutrophils and monocytes by counting a minimum of 200 cells and expressing the results as a percentage of total cells.

15 Alternatively, OA sensitized Guinea Pigs (\pm compound) were exposed to OA via inhalation 24 h after OA exposure and lungs were obtained as described above and assessed for eosinophil infiltration.

The following examples are illustrative but not limiting of the embodiments of the present invention.

Example 1

20 (S)-2-[2-(1-naphthoylamino)-3-(4-nitrophenyl)propionylamino]-(*N*-phenyl)propionamide

a) (S)-2-[2-(1-naphthoylamino)-3-(4-nitrophenyl)propionylamino]propionic acid
(S)-2-[2-(1-naphthoylamino)-3-(4-nitrophenyl) propionylamino]propionic acid

25 tertbutyl ester (3.0 g, 6.1 mmol) was dissolved in 1:1 trifluoroacetic acid:methylene chloride (10 mL) and allowed to stir at room temperature for 5 h. The solvent was evaporated in vacuo, and the resulting solid was washed with diethyl ether to furnish the product (2.2 g, 83%) as a white powder. MS (ES+) m/e 436 [M+H]⁺, 458

30 b) (S)-2-[2-(1-naphthoylamino)-3-(4-nitrophenyl)propionylamino]-*N*-phenyl)propionamide

The compound from (a) above (0.1 g, 0.23 mmol) was dissolved in THF (15 mL) and the solution cooled to -20°C before the addition of N-methylmorpholine (0.046g, 0.46 mmol) and isobutylchloroformate (0.03g, 0.22 mmol). After stirring for 10 min, aniline (0.02g, 0.21 mmol) was added and the reaction mixture was 5 stirred at 25°C for 1 h. Solids were removed, the filtrate was evaporated to dryness and the residue in ethyl acetate (20 mL). The solution was washed with water, dried (MgSO₄) and evaporated to a white solid which was titrated with ether and filtered to give the title compound (0.04g) MS (ES-) m/e 509 [M-H]⁻, 555, 1065.

10 Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.

Example 2

15 **1-Benzyl-3-(S)-(N-(1-naphthyl)amino)-4-(4-nitrophenyl)-2-butanone**

A. 1-Chloro-3-(S)-(N-*t*butyloxycarbonylamino)-4-(4-nitrophenyl)-2-butanone
*t*Butyloxycarbonyl-4-nitrophenylalanine (2.0g, 6.4 mmol) was dissolved in dry THF (15 mL) and the solution cooled to -25°C. N-Methylmorpholine (0.8g, 7.9 mmol) was added followed by isobutyl chloroformate (0.9g, 6.6 mmol) at a rate such that 20 the temperature did not exceed -25°C. After 5 minutes dry ether (20 mL) was added while cooling the reaction to -70°C. The mixture was filtered under argon and the filtrate treated with an ethereal solution of diazomethane (64 mmol). The mixture was allowed to warm to room temperature over 1h and stirred for an additional 2 hours. Excess diazomethane was purged with nitrogen, the solution evaporated and 25 the residue taken up in ethyl acetate (50 mL). The solution was washed with saturated aqueous sodium bicarbonate, brine, dried (MgSO₄) and evaporated to a pale solid. The solid was taken up in dry dioxane (25 mL), the solution cooled to 0°C and treated with a 4N solution of HCl in dioxane (16 mL, 64 mmol). The reaction mixture was stirred at room temperature for 20min and was evaporated to a 30 light yellow solid which was washed with ether and filtered to give the title compound as a white solid (1.7g 78%).

B. 1-Hydroxy-3-(S)-(N-*t*butyloxycarbonylamino)-4-(4-nitrophenyl)-2-butanone
Sodium iodide (135mg, 0.9 mmol) was added to a stirred solution of the substrate (300mg, 0.9 mmol) in acetone (5 mL). After 15 minutes, diisopropylethyl amine 35 (0.2g, 1.6 mmol) was added followed by a solution of benzoyl formic acid (160mg, 1.1 mmol) in acetone in (0.5 mL). After 16h, the mixture was evaporated, the residue

partitioned between water and ethyl acetate. The organic layer was dried (MgSO_4), concentrated and the residue dissolved in 2 mL THF. Aqueous potassium hydrogen carbonate (1M, 1 mL) was added and the reaction mixture was stirred for 3 days and partitioned between ethyl acetate and water. Drying (MgSO_4) and evaporation of the organic extracts gave the title compound as an oil (200mg, 69%)

5 C. 1-Benzyl-3-(S)-(N-*t*butyloxycarbonylamino)-4-(4-nitrophenyl)-2-butanone
 To a dichloromethane solution of 1-hydroxy-3-(S)-(N-*t*butyloxycarbonylamino)-4-(4-nitrophenyl)-2-butanone (250mg, 0.8 mmol in 10 mL of dichloromethane) were added silver(II)oxide (0.4g, 1.7 mmol) and benzyl bromide (137mg, 0.8 mmol). The

10 reaction mixture was refluxed for 16h filtered through Celite, concentrated and the residue purified by column chromatography (3:7 hexane:ethyl acetate) to give the title compound as a white solid (170mg, 51%)

D. 1-Benzyl-3-(S)-(N-(1-naphthoyl)amino)-4-(4-nitrophenyl)-2-butanone
 1-Benzyl-3-(S)-(N-*t*butyloxycarbonylamino)-4-(4-nitrophenyl)-2-butanone
 15 (170mg, 0.4 mmol) was treated with 4M HCl in dioxane (1 mL, 4 mmol). After stirring for 1h, dioxane was evaporated, the residue suspended in the THF (5 mL) and treated with 1-naphthoylchloride (76mg, 0.4 mmol) and aqueous sodium hydroxide (30mg, 7.5 mmol in 1 mL water). The reaction mixture was stirred for 30min and partitioned between ethyl acetate and water. Drying (MgSO_4) and
 20 evaporation of the organic layer gave a crude product which was further purified by column chromatography (1:1 hexane:ethyl acetate) to give the title compound as a light yellow solid (20mg, 11%) MS (ES+) m/e 469 [M+H]⁺, 491.

Example 3

25

Inhalant Formulation

A present compound (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.

30

Example 4

Tablet Formulation

Tablets/Ingredients

1. Present compound

Per Tablet

40 mg

2. Corn Starch

20 mg

35 3. Alginic acid

20 mg

4.	Sodium Alginat	20 mg
5.	Mg stearate	1.3 mg

Procedure for tablet formulation:

5 Ingredients 1, 2, 3 and 4 are blended in a suitable mixer/blender. Sufficient water is added portion-wise to the blend with careful mixing after each addition until the mass is of a consistency to permit its conversion to wet granules. The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen. The wet granules are then dried in an oven at 140°F (60°C) until dry. The dry granules are lubricated with ingredient No. 5, and the lubricated granules are compressed on a suitable tablet press.

Example 5

Parenteral Formulation

15 A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a present compound in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then rendered sterile by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

20 All publications, including but not limited to patents and patent applications cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference as though fully set forth.

What is claimed is:

1. (S)-2-[2-(1-naphthoylamino)-3-(4-nitrophenyl)propionylamino]-(*N*-phenyl)propionamide, or *N*-(2-bromophenyl)-*N'*-[4-chloro-2-hydroxy-3-(1-oxidothiomorpholinosulfonyl)phenyl] urea, or a pharmaceutically acceptable salt thereof.
2. A method according to claim 1 wherein the compound is (S)-2-[2-(1-naphthoylamino)-3-(4-nitrophenyl)propionylamino]-(*N*-phenyl)propionamide
3. A method according to claim 1 wherein the compound is *N*-(2-bromophenyl)-*N'*-[4-chloro-2-hydroxy-3-(1-oxidothiomorpholinosulfonyl)phenyl] urea.
4. A method of antagonizing a CCR-3 receptor by administering a compound according to claim 1.
5. A method of treating an allergic disease comprising administering to a patient in need of treatment a safe and effective amount of a compound according to claim 1.
6. A method according to claim 4 wherein the disease is selected from the group consisting of bronchial asthma, eczema, conjunctivitis, allergic rhinitis, nasal polyposis, atopic dermatitis, pruritis and inflammatory bowel disease.

20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/01252

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/17, 31/541; C07C 275/18, 275/28; C07D 279/12
 US CL : 514/227.5, 594; 544/59; 564/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/227.5, 594; 544/59; 564/48

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
 NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 STN, Medline

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	WO 99/55330 (DHANAK ET AL) 04 November 1999 (04-11-99), see entire document.	1-6
A, P	WO 99/55324 (D. DHANAK) 04 November 1999 (04-11-99), see entire document.	1-6

Further documents are listed in the continuation of Box C.

See patent family annex.

Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	*&*	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

23 MARCH 2000

Date of mailing of the international search report

19 MAY 2000

Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PHYLLIS SPIVACK

Telephone No. (703) 308-1235